行情

GLYC

GLYC

GlycoMimetics
NASDAQ

实时行情|Nasdaq Last Sale

4.890
+0.030
+0.62%
盘后: 4.890 0 0.00% 16:00 01/17 EST
开盘
4.930
昨收
4.860
最高
5.06
最低
4.880
成交量
15.78万
成交额
--
52周最高
13.56
52周最低
2.640
市值
2.12亿
市盈率(TTM)
-3.7009
分时
5日
1月
3月
1年
5年

分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

GLYC 新闻

  • 沪指震荡上扬 中国央行4天投放1.1万亿
  • 新浪财经.40分钟前
  • 英媒刊文:生产率下滑正困扰新兴经济体
  • 参考消息.4小时前
  • 戈恩为何决定逃亡?日媒揭秘:或因听闻审理将延期
  • 中国新闻网.4小时前
  • 日媒:戈恩从日本逃往黎巴嫩或因听闻审理将延期
  • 新京报网.4小时前

更多

所属板块

生物技术和医学研究
-0.16%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

GLYC 简况

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
展开

Webull提供GlycoMimetics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。